Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 8/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084766 | 0.89 | NOD1 (0.63) | NOD1TLR2GLP1RLPAR3EPHX2 | |
| SCHEMBL45887 | 0.86 | GLP1R (0.57) | NOD1TLR2GLP1RLPAR3SIRT2 | |
| SCHEMBL22386556 | 0.84 | NAAA (0.61) | NOD1TLR2GLP1REPHX2ALB | |
| SCHEMBL45885 | 0.84 | GLP1R (0.56) | NOD1TLR2GLP1RLPAR3SIRT2 | |
| SCHEMBL16525843 | 0.84 | GLP1R (0.56) | NOD1TLR2GLP1RLPAR3SIRT2 | |
| SCHEMBL20029386 | 0.84 | NOD1 (0.50) | NOD1TLR2GLP1RLPAR3SIRT2 | |
| SCHEMBL28960756 | 0.83 | NOD1 (0.61) | NOD1TLR2GLP1R | |
| SCHEMBL28960755 | 0.83 | NOD1 (0.61) | NOD1TLR2GLP1R | |
| SCHEMBL26973001 | 0.83 | TLR2 (0.51) | NOD1TLR2GLP1RLPAR3SIRT2 | |
| SCHEMBL23191719 | 0.83 | CASP2 (0.62) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360488-A1 | PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360488-A1 | PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS | PTH1R, PTMS, FGF23 | NOD1 3030/4885TLR2 3753/4885GLP1R 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.